<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00214110</url>
  </required_header>
  <id_info>
    <org_study_id>2000-486</org_study_id>
    <nct_id>NCT00214110</nct_id>
  </id_info>
  <brief_title>Tamoxifen Therapy in Amyotrophic Lateral Sclerosis [ALS]</brief_title>
  <official_title>Phase 2 Randomized Single-blind Escalating Dose Response Clinical Trial of Tamoxifen Therapy on Mean Percent Predicted Isometric Strength in Amyotrophic Lateral Sclerosis [ALS]</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Wisconsin, Madison</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Wisconsin, Madison</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-center, phase 2 randomized clinical trial of tamoxifen on mean percent&#xD;
      predicted isometric muscle strength in patients with amyotrophic lateral sclerosis (ALS). The&#xD;
      purpose is to determine whether the triphenylethylenetamoxifen, used as adjuvant therapy in&#xD;
      the treatment of breast cancer, can delay the loss of isometric muscle strength in ALS&#xD;
      patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2001</start_date>
  <completion_date type="Actual">January 2005</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Single</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Stability at 6, 12, 18 and 24 months on of the patient's mean percent predicted arm strength</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Vital capacity, raw liters and percent predicted, compared with baseline measured at 3 month intervals.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Individual arm and leg muscle mean percent predicted isometric strength compared with baseline measured at 3 month intervals.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bulbar, Breathing, arm and leg subscores of ALS Functional Rating Scale - Revised [ALS-FRS-R] compared with baseline measured at 3 month intervals.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total ALS Functional Rating Scale [ALS-FRS-R] compared with baseline measured at 3 month intervals.</measure>
  </secondary_outcome>
  <enrollment>100</enrollment>
  <condition>Amyotrophic Lateral Sclerosis (ALS)</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tamoxifen</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  clinically probable-laboratory supported, clinically probable, or clinically definite&#xD;
             amyotrophic lateral sclerosis&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Allergic or idiosyncratic response to tamoxifen.&#xD;
&#xD;
          -  Other active neurologic diseases that may produce weakness, sensory loss, or autonomic&#xD;
             symptoms.&#xD;
&#xD;
          -  Psychiatric, psychological, or behavioral symptoms that would interfere with the&#xD;
             subject's ability to participate in the trial.&#xD;
&#xD;
          -  Clinically significant cardiac, pulmonary, gastrointestinal, hematologic, or endocrine&#xD;
             (poorly controlled insulin-dependent diabetes mellitus or hyperthyroidism) disease&#xD;
             that may confound interpretation of the study results.&#xD;
&#xD;
          -  Previous kidney or pancreas transplants.&#xD;
&#xD;
          -  Significant hepatic or renal disease (AST &gt; 5 times normal, serum creatinine &gt; 2.0&#xD;
             mg/dL for males or &gt; 1.8 mg/dL for females).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Benjamin R Brooks, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Wisconsin, Madison</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Wisconsin</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2008</verification_date>
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2005</study_first_posted>
  <last_update_submitted>October 1, 2015</last_update_submitted>
  <last_update_submitted_qc>October 1, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 5, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tamoxifen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

